Susquehanna International Group’s Autolus Therapeutics AUTL Stock Holding History

Susquehanna International Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60.4K	Buy	43,800 +26,500	+153%	+$40.3K	﹤0.01%	12579
2025 Q4	$34.4K	Buy	+17,300	New	+$26.6K	﹤0.01%	11851
2024 Q3	–	Sell	-22,500	Closed	-$78.3K	–	11931
2024 Q2	$78.3K	Sell	22,500 -60,600	-73%	-$262K	﹤0.01%	11185
2024 Q1	$530K	Sell	83,100 -16,700	-17%	-$104K	﹤0.01%	8362
2023 Q4	$643K	Sell	99,800 -42,500	-30%	-$162K	﹤0.01%	8061
2023 Q3	$332K	Buy	142,300 +49,800	+54%	+$142K	﹤0.01%	9146
2023 Q2	$220K	Buy	+92,500	New	+$219K	﹤0.01%	10085
2023 Q1	–	Sell	-15,800	Closed	-$30K	–	12533
2022 Q4	$30K	Buy	+15,800	New	+$40K	﹤0.01%	11621
2022 Q3	–	Sell	-10,500	Closed	-$30K	–	13129
2022 Q2	$30K	Sell	10,500 -33,700	-76%	-$103K	﹤0.01%	12219
2022 Q1	$184K	Sell	44,200 -4,800	-10%	-$20.2K	﹤0.01%	11334
2021 Q4	$254K	Sell	49,000 -2,500	-5%	-$15K	﹤0.01%	10886
2021 Q3	$337K	Buy	+51,500	New	+$325K	﹤0.01%	10322

Other funds holding AUTL

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's AUTL Position: Q1 2026 in Review

Susquehanna International Group reduced its Autolus Therapeutics (AUTL) stake by 33% in Q1 2026, selling an estimated $304K and leaving 399,143 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #9409.

Susquehanna International Group first reported a position in AUTL in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.19M in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

Susquehanna International Group held 399,143 shares of Autolus Therapeutics worth $551K as of Q1 2026.
Susquehanna International Group sold 199,844 Autolus Therapeutics shares in Q1 2026, an estimated $304K.
Autolus Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9409 holding.
Susquehanna International Group first reported a position in Autolus Therapeutics in Q4 2021 and has held it in 15 quarters since.
Susquehanna International Group's Autolus Therapeutics position peaked at $1.19M in Q4 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.